Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Thromb Haemost. 2021 Feb 10;19(4):1001–1017. doi: 10.1111/jth.15236

FIGURE 4.

FIGURE 4

Atherosclerosis assessment in 14E11- and FXI-ASO-treated Ldlr−/− mice on 16 weeks of HFD. (A) At 8 weeks of HFD, hyperlipidemic Ldlr−/− mice were randomized and administered 14E11 (4 mg/kg) and FXI-ASO (7.5 mg/kg) weekly until 16 weeks of HFD. (B) Atherosclerotic lesion area in the proximal aortas, quantified under light microscopy. Scale bar = 1 mm. (D) Cross-sections of aortic sinus were obtained and atherosclerotic lesion area was determined by ORO staining (red, ×105 μm2). Scale bar = 200 μm. (D) Total plasma cholesterol at week 8 before randomization into treatment groups and 16 weeks of HFD in Ldlr−/− mice. (E) Monocyte-platelet aggregates and (F) Ly6Chigh, shown as % of total monocytes at 8 weeks of HFD before treatments and 8 weeks of HFD in vehicle-, 14E11-, and FXI-ASO-treated animals. Data were analyzed using Kruskal-Wallis with Dunn post hoc test. **p < .005. ***p < .0001